Marc Riedl, MD

UC San Diego, La Jolla, California, United States · UCSD

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Marc Riedl, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:53 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT05047185 · Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Pharvaris Netherlands B.V. · terminated · Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II · principal investigator
Ph2/Ph3
NCT02303626 · 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
BioCryst Pharmaceuticals · completed · Hereditary Angioedema, HAE · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 05:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name.